Daratumumab

达雷妥尤单抗

Report date: 2026/04/25 20:00:23
First In Class

Base Information

Drug NameDaratumumab
Drug Alias Name达雷木单抗HuMax-CD38达雷妥木单抗daratumumabumHumanised anti-CD38 monoclonal antibody +[10] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsComplement dependent cytotoxicity (CDC) effectsAnti-CD38 +[4] 
TargetsLymphocyte differentiation antigen CD38
Therapy Area/IndicationsRejection of organ transplantationRejection of renal transplantationHypersensitivity +[37] 
Global Approved IndicationsMultiple Myeloma
Approved Indications in ChinaMultiple Myeloma
Original Approved Country/TerritoryUnited States
Original Approved Date2015/11/16
Country/TerritoryCzechiaBelgiumBulgaria +[43] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesJohnson & Johnson Innovative Medicine
China Registration ClassN/A

Develop Information

Active CompaniesJanssen, L.P. - Investigator Initiated Studies ProgramDana-Farber Cancer InstituteJohnson & Johnson Innovative Medicine +[27] 
Inactive CompaniesJanssen-Cilag Div. Of Johnson&Johnson SeWake Forest University Health SciencesWashington University School Of Medicine +[7] 
Active IndicationsRejection of organ transplantationRejection of renal transplantationHypersensitivity +[27] 
Inactive IndicationsLupus Erythematosus, SystemicMyelodysplastic SyndromesProstatic Neoplasms +[10] 

Other Information

ATC CodeL01XC24
Related LinksWikipediaDrugBankKEGG